
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen Inc. is approaching significant clinical milestones for its product candidates, particularly SZN-8141, which is expected to enter clinical trials, enhancing investor confidence in the company's potential to address unmet needs in retinal diseases such as wet AMD and DME. The recent achievement of a research milestone with strategic partner Boehringer Ingelheim, leading to a $5 million payment for SZN-413, not only underscores strong validation for Surrozen's development efforts but also provides financial support for advancing its internal Wnt assets. Additionally, preclinical successes for SZN-413 indicate the viability of Surrozen’s broader pipeline, suggesting that its innovative Wnt pathway modulation may significantly improve treatment durability for patients facing standard anti-VEGF therapies.
Bears say
Surrozen Inc faces significant financial challenges, including the potential inability to secure capital on favorable terms, which could negatively impact stock performance. The company's reliance on its developmental candidates achieving peak commercial revenue estimates is jeopardized by uncertainties related to market size and penetration, as well as possible adverse outcomes from ongoing clinical programs such as SZN-8141. Additionally, the risk of unexpected toxicity in early studies and the potential failure of associated studies, such as Merck’s Restore trial, could undermine investor confidence in the viability of the Wnt agonist class for retinal disease treatment.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares